# US 2022/0016054 A1 · Epinephrine parenteral formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016054 A1
- Document ID: US20220016054A1
- Status: Published application
- Kind: A1
- Application number: 17/378,089
- Filed: 2021-07-16
- Published: 2022-01-20
- Earliest claimed: 2020-07-20
- Assignees: Somerset Therapeutics, LLC
- Applicants: Somerset Therapeutics LLC
- Inventors: Mandar V. Shah; Santhosh Kamath; Sathiyamoorthi Natarajan; Ilango Subramanian; Veerappan Subramanian
- Web page: https://patentgrep.com/patent/US20220016054A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to liquid formulations of epinephrine or a pharmaceutically acceptable salt thereof intended for parenteral administration. In particular, the invention provides liquid formulations comprising levorotatory-epinephrine (l-epinephrine) in a concentration of about 0.5 to about 1.5 mg/mL and at least one antioxidant. The antioxidant is selected from the group consisting of ascorbic acid, sodium ascorbate, monothioglycerol, vitamin-A, vitamin-B1, vitamin-B2, vitamin-B6, vitamin-E, butylated hydroxy toluene, butylated hydroxy anisole and propyl gallate, alone or in a combination. The formulations prepared by using the current invention exhibit good physical and chemical stability.

## Claims

### Claim 1

A liquid composition consisting essentially of levorotatory-epinephrine (l-epinephrine) in a concentration of about 0.5 to about 1.5 mg/mL, tartaric acid in a concentration of about 0.1 to about 4.0 mg/mL, sodium edetate in a concentration of about 0.1 to about 0.5 mg/mL, sodium chloride in a concentration of about 4.0 to about 9.0 mg/mL and water, wherein the composition is free of bisulfite as an antioxidant.

### Claim 2 (depends on 1)

The liquid composition of claim 1, wherein the l-epinephrine is in a concentration of about 1.0 mg/mL.

### Claim 3 (depends on 1)

The liquid composition of claim 1, wherein the composition has an enantiomeric purity of l-epinephrine of greater than about 92%.

### Claim 4 (depends on 1)

The liquid composition of claim 1, wherein the composition is in the form of a solution for intravenous, subcutaneous or intramuscular administration.

### Claim 5 (depends on 1)

The liquid composition of claim 1, wherein the composition is 1 mg/mL of l-epinephrine sterile injection solution.

### Claim 6 (depends on 1)

The liquid composition of claim 1, wherein the concentration of tartaric acid is about 2.25 mg/mL, sodium edetate in a concentration of about 0.2 mg/mL, sodium chloride in a concentration of about 6.15 mg/mL and water.

### Claim 7 (depends on 1)

The liquid composition of claim 1, wherein the composition further comprises chlorobutanol as preservative.

### Claim 8 (depends on 1)

The liquid composition of claim 1, wherein the composition has a pH of about 2.5 to about 3.5.

### Claim 9 (depends on 1)

The liquid composition of claim 1, wherein the composition is a solution filled in a vial, an ampoule, a bag, a bottle, a cartridge, or a syringe.

### Claim 10 (depends on 1)

The liquid composition of claim 1, wherein the composition is stable for at least 12 months when stored at 25±2° C. and 60% relative humidity.

### Claim 11 (depends on 1)

The liquid composition of claim 1, wherein the composition comprises about 10% or less total impurities after 3 months on storage at about 25° C. and 60% RH and or about 40° C. and 75% RH, wherein the impurities comprise norepinephrine, epinine, oxedrine, adrenalone, methoxy analog Impurity-F, N-benzyl epinephrine, N-benzyl adrenalone and or any other unknown impurity.

### Claim 12 (depends on 1)

The liquid composition of claim 1, wherein the composition does not undergo unacceptable colour change after 3 months on storage at about 25° C. and 60% RH and or about 40° C. and 75% RH.

### Claim 13

A liquid composition consisting essentially of levorotatory-epinephrine (l-epinephrine) in a concentration of about 0.5 to about 1.5 mg/mL, tartaric acid in a concentration of about 0.1 to about 4.0 mg/mL, sodium edetate in a concentration of about 0.1 to about 0.5 mg/mL, sodium chloride in a concentration of about 4.0 to about 9.0 mg/mL, optional sodium hydroxide to adjust pH, optional hydrochloric acid to adjust pH, and water, wherein the composition is free of bisulfite as an antioxidant and the composition has a pH in the range of about 2.5 to about 3.5.

### Claim 14 (depends on 13)

The liquid composition of claim 13, wherein the composition consists of the l-epinephrine, tartaric acid in a concentration of about 2.25 mg/mL, sodium edetate in a concentration of about 0.2 mg/mL, sodium chloride in a concentration of about 7.3 mg/mL, the optional sodium hydroxide to adjust pH, the optional hydrochloric acid to adjust pH, and water.

### Claim 15

A liquid injection composition of l-epinephrine in a concentration of about 1.0 mg/mL, citric acid in a concentration of about 0.1 to about 4.0 mg/mL, sodium edetate in a concentration of about 0.1 to about 0.5 mg/mL, sodium chloride in a concentration of about 4.0 to about 9.0 mg/mL water and at least one antioxidant, wherein the antioxidant is selected from the group consisting of ascorbic acid, sodium ascorbate, monothioglycerol, vitamin-A, vitamin-B1, vitamin-B2, vitamin-B6, vitamin-E, butylated hydroxy toluene, butylated hydroxy anisole and propyl gallate, alone or in a combination thereof, in a concentration of about 0.2 to about 5.0 mg/mL and the composition is free of bisulfite.
